OTCPK:SGMOBiotechs
Assessing Sangamo Therapeutics (SGMO) Valuation After New Fabry Data Financing Move And Leadership Changes
Clinical and financing moves put Sangamo Therapeutics (SGMO) in focus
Sangamo Therapeutics (SGMO) moved into the spotlight after releasing detailed Phase 1/2 STAAR study data for its Fabry gene therapy candidate, alongside a US$25 million follow on equity offering and a change in its finance leadership.
See our latest analysis for Sangamo Therapeutics.
Against this backdrop of clinical data, financing and leadership change, Sangamo Therapeutics’ share price has been under pressure, with a 30...